UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Breast cancer research and treatment, 2018, Vol.167 (1), p.123-131

2018

Volltextzugriff (PDF)

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial

Annals of oncology, 2014-04, Vol.25 (4), p.816-823

2014

Volltextzugriff (PDF)

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis

Breast cancer research and treatment, 2014-12, Vol.148 (3), p.599-613

2014

Volltextzugriff (PDF)

Hereditary melanoma and predictive genetic testing: why not?

Psycho-oncology (Chichester, England), 2005-09, Vol.14 (9), p.738-745

2005

Volltextzugriff (PDF)

Iatrogenic melanoma. Comment on: Melanoma epidemic: a midsummer night's dream?

British journal of dermatology (1951), 2010-02, Vol.162 (2), p.457-458

2010

Volltextzugriff (PDF)

European inter-institutional impact study of MammaPrint

Breast (Edinburgh), 2014-08, Vol.23 (4), p.423-428

2014

Volltextzugriff (PDF)

Erratum to: Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis

Breast cancer research and treatment, 2015, Vol.149 (2), p.567-567

2015

Volltextzugriff (PDF)

MT21 Clinical Application of Circulating Tumor Cells in Melanoma Patients: Overview of Current Available Data

Value in health, 2023-12, Vol.26 (12), p.S430

2023

Volltextzugriff (PDF)

MT37 Clinical Utility of Circulating Tumor Cell (CTC) Enumeration-Based Liquid Biopsy and HER2 CTC Assessment in Patients with Metastatic Breast Cancer: Overview of Current Available Data and Interventional Trials

Value in health, 2023-12, Vol.26 (12), p.S433

2023

Volltextzugriff (PDF)

CO119 Clinical Utility of Circulating Tumor Cell Enumeration-Based Liquid Biopsy in Patients with Metastatic Breast Cancer: A Review of the Peer-Reviewed Clinical Literature

Value in health, 2023-06, Vol.26 (6), p.S37-S37

2023

Volltextzugriff (PDF)

P204 Microarray based determination of ER, PR and HER2 receptor status compared to local ICH/FISH assessment in 641 patients

Breast (Edinburgh), 2011, Vol.20, p.S45-S45

2011

Volltextzugriff (PDF)

0075 Use of the genomic test MammaPrint in daily clinical practice to assist in risk stratification of young breast cancer patients

Breast (Edinburgh), 2009, Vol.18, p.S37-S37

2009

Volltextzugriff (PDF)

117 Development and validation of an array based Molecular Subtyping Profile for breast cancer

European journal of cancer supplements, 2010, Vol.8 (3), p.93-93

2010

Volltextzugriff (PDF)

Microarray analysis as a helpful tool in identifying the primary tumour in cancer with an unknown primary site

Netherlands journal of medicine, 2010-01, Vol.68 (1), p.50

2010

Volltextzugriff (PDF)

Chemosensitivity Predicted By Mammaprint and Blueprint in the Prospective Neo-Adjuvant Breast Registry Symphony Trial (Nbrst)

Annals of oncology, 2014-09, Vol.25, p.iv87

2014

Volltextzugriff (PDF)

260PDCHEMOSENSITIVITY PREDICTED BY MAMMAPRINT AND BLUEPRINT IN THE PROSPECTIVE NEO-ADJUVANT BREAST REGISTRY SYMPHONY TRIAL (NBRST)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv87-iv88

2014

Volltextzugriff (PDF)

0063 Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients (PATH) with early stage breast cancer

Breast (Edinburgh), 2009, Vol.18, p.S34-S34

2009

Volltextzugriff (PDF)

Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy

Annals of oncology, 2017-09, Vol.28, p.v606-v606

2017

Volltextzugriff (PDF)

0074 Early prognosis prediction: MammaPrint on core-needle biopsies

Breast (Edinburgh), 2009, Vol.18, p.S37-S37

2009

Volltextzugriff (PDF)

Immunohistochemical versus molecular

Breast cancer research and treatment, 2018-01, Vol.167 (1), p.123

2018

Volltextzugriff (PDF)

5167 French cost effectiveness study of the MammaPrint 70-gene signature in early stage breast cancer patients

European journal of cancer supplements, 2009, Vol.7 (2), p.310-310

2009

Volltextzugriff (PDF)

Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.PD7-01-PD7-01

2017

Volltextzugriff (PDF)

Abstract P2-11-23: MammaPrint and BluePrint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-11-23

2013

Volltextzugriff (PDF)

Abstract P1-02-02: Concordance of microarray based determination of ER, PR and HER2 receptor status and local IHC/FISH assessment in the prospective neo-adjuvant breast registry symphony trial (NBRST)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-02-02

2013

Volltextzugriff (PDF)

Abstract P1-08-02: Chemosensitivity and endocrine sensitivity of MammaPrint and BluePrint in the prospective neo-adjuvant breast registry symphony trial (NBRST)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-08-02

2013

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(114)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(51)
Biological And Medical Sciences
(24)
Humans
(21)
Environmental Sciences & Ecology
(16)
Ecology
(15)
Female
(15)
Medical Sciences
(14)
Oncology
(14)
Biodiversity
(13)
Adult
(12)
Fundamental And Applied Biological Sciences. Psychology
(12)
Middle Aged
(12)
Melanoma - Genetics
(11)
Aged
(10)
Male
(10)
Skin Neoplasms - Genetics
(10)
Birds
(9)
Environmental Sciences
(9)
Agricultural Land
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis

Hereditary melanoma and predictive genetic testing: why not?

Iatrogenic melanoma. Comment on: Melanoma epidemic: a midsummer night's dream?

European inter-institutional impact study of MammaPrint

Erratum to: Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis

MT21 Clinical Application of Circulating Tumor Cells in Melanoma Patients: Overview of Current Available Data

MT37 Clinical Utility of Circulating Tumor Cell (CTC) Enumeration-Based Liquid Biopsy and HER2 CTC Assessment in Patients with Metastatic Breast Cancer: Overview of Current Available Data and Interventional Trials

CO119 Clinical Utility of Circulating Tumor Cell Enumeration-Based Liquid Biopsy in Patients with Metastatic Breast Cancer: A Review of the Peer-Reviewed Clinical Literature

P204 Microarray based determination of ER, PR and HER2 receptor status compared to local ICH/FISH assessment in 641 patients

0075 Use of the genomic test MammaPrint in daily clinical practice to assist in risk stratification of young breast cancer patients

117 Development and validation of an array based Molecular Subtyping Profile for breast cancer

Microarray analysis as a helpful tool in identifying the primary tumour in cancer with an unknown primary site

Chemosensitivity Predicted By Mammaprint and Blueprint in the Prospective Neo-Adjuvant Breast Registry Symphony Trial (Nbrst)

260PDCHEMOSENSITIVITY PREDICTED BY MAMMAPRINT AND BLUEPRINT IN THE PROSPECTIVE NEO-ADJUVANT BREAST REGISTRY SYMPHONY TRIAL (NBRST)

0063 Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients (PATH) with early stage breast cancer

Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy

0074 Early prognosis prediction: MammaPrint on core-needle biopsies

Immunohistochemical versus molecular

5167 French cost effectiveness study of the MammaPrint 70-gene signature in early stage breast cancer patients

Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Abstract P2-11-23: MammaPrint and BluePrint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping

Abstract P1-02-02: Concordance of microarray based determination of ER, PR and HER2 receptor status and local IHC/FISH assessment in the prospective neo-adjuvant breast registry symphony trial (NBRST)

Abstract P1-08-02: Chemosensitivity and endocrine sensitivity of MammaPrint and BluePrint in the prospective neo-adjuvant breast registry symphony trial (NBRST)

Suchergebnisse filtern